{
    "clinical_study": {
        "@rank": "127581", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 AGS-16C3F highest dose", 
                "arm_group_type": "Experimental", 
                "description": "Renal Cell Carcinoma subjects with clear and non-clear histology"
            }, 
            {
                "arm_group_label": "Cohort 0 AGS-16C3F higher dose", 
                "arm_group_type": "Experimental", 
                "description": "Renal Cell Carcinoma subjects with clear and non-clear histology"
            }, 
            {
                "arm_group_label": "Cohort (-1) AGS-16C3F high dose", 
                "arm_group_type": "Experimental", 
                "description": "Renal Cell Carcinoma subjects with clear and non-clear histology"
            }, 
            {
                "arm_group_label": "Cohort (-2) AGS-16C3F middle dose", 
                "arm_group_type": "Experimental", 
                "description": "Renal Cell Carcinoma subjects with clear and non-clear histology"
            }, 
            {
                "arm_group_label": "Cohort (-3) AGS-16C3F low dose", 
                "arm_group_type": "Experimental", 
                "description": "Renal Cell Carcinoma subjects with clear and non-clear histology"
            }, 
            {
                "arm_group_label": "Cohort (-4) AGS-16C3F lowest dose", 
                "arm_group_type": "Experimental", 
                "description": "Renal Cell Carcinoma subjects with clear and non-clear histology"
            }, 
            {
                "arm_group_label": "AGS-16C3F in RCC Subjects with  Clear Cell Histology", 
                "arm_group_type": "Experimental", 
                "description": "Expansion Cohort"
            }, 
            {
                "arm_group_label": "AGS-16C3F in RCC Subjects with  Papillary Histology", 
                "arm_group_type": "Experimental", 
                "description": "Expansion Cohort"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and pharmacokinetics and assess the\n      immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC)."
        }, 
        "brief_title": "A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Carcinoma, Renal Cell", 
            "Renal Cell Carcinoma With Clear Cell Histology", 
            "Renal Cell Carcinoma With Non-Clear Cell Histology", 
            "Renal Cell Carcinoma of Papillary Histology"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study has two components.  The first aims to establish a safe dose for AGS-16C3F.  Once\n      identified, the safety and effectiveness will be tested in additional subjects with either\n      clear cell or papillary histology in expanded cohorts."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Dose determination cohorts:  Histologically confirmed diagnosis of metastatic RCC of\n             either clear cell or non-clear histology.\n\n               -  Tumors with clear cell histology: subject must have progressed after at least\n                  one anti-vascular endothelial growth factor receptor (anti-VEGFR) therapy\n\n               -  Tumors with non-clear cell histology must be ectonucleotide\n                  pyrophosphatase/phosphodiesterase family member 3 (ENPP3) positive at\n                  pre-screening. This sub-group does not have any prior therapy requirement.\n\n          -  Dose expansion cohorts:  Histologically confirmed diagnosis of metastatic RCC of\n             either clear cell or papillary histology\n\n               -  Tumors with clear cell histology: subject must have progressed after at least\n                  one anti-VEGFR therapy\n\n               -  Tumors with papillary histology: includes unclassified histology with papillary\n                  features and must be ENPP3 positive at pre-screening. This sub-group does not\n                  have any prior therapy requirement.\n\n          -  Measurable disease according to Response Criteria for Solid Tumors (RECIST Version\n             1.1)\n\n          -  Eastern Cooperative Group (ECOG) performance status of 0-1\n\n          -  Hematologic function, as follows:\n\n               -  Absolute neutrophil count (ANC) \u2265 1.5 x 109/L\n\n               -  Platelet count \u2265 100 x 109/L\n\n               -  Hemoglobin \u2265 9 g/dL (transfusions are allowed)\n\n          -  Renal function, as follows:\n\n               -  creatinine \u2264 1.5 x upper limit of normal (ULN), or calculated glomerular\n                  filtration rate (GFR) > 50 mL/min if creatinine > 1.5x ULN\n\n          -  Hepatic function, as follows:\n\n               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \u2264 2.5 x ULN\n                  or \u2264 5x ULN if known liver metastases\n\n               -  Total bilirubin \u22641.5 x ULN\n\n          -  International normalized ratio (INR) < 1.3 (or \u2264 3.0 if on therapeutic\n             anticoagulation)\n\n          -  Women and men of childbearing potential must be advised and agree to practice\n             effective methods of contraception during the course of the study and for 4 weeks\n             after the last AGS-16C3F infusion administration\n\n        Exclusion Criteria:\n\n          -  Current uncontrolled central nervous system (CNS) metastasis or malignant brain\n             tumors\n\n          -  Use of any investigational drug (including marketed drugs not approved for this\n             indication) within 4 weeks prior to screening. No time limit applies to the use of\n             marketed drugs approved for this indication provided that the subject has progressed\n             on the treatment and all toxicities attributable to the drug have resolved or\n             returned to baseline\n\n          -  Known sensitivity to any of the ingredients of the investigational product AGS-16C3F\n\n          -  History of thromboembolic events and bleeding disorders \u22643 months (e.g., (deep vein\n             thrombosis) DVT or pulmonary embolism (PE))\n\n          -  Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart\n             Association CHF Functional Classification System) or clinically significant cardiac\n             disease within 12 months of study enrollment, including myocardial infarction,\n             unstable angina, grade 2 or greater peripheral vascular disease, congestive heart\n             failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient\n             medication.\n\n          -  Major surgery within 4 weeks of study enrollment\n\n          -  Women who are pregnant (confirmed by positive pregnancy test) or lactating\n\n          -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis\n             B surface antigen.\n\n          -  Active infection requiring treatment with systemic (intravenous or oral)\n             anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of\n             screening.\n\n          -  History of eye surgery within 6 months, presence of cataracts or other ocular\n             disorders significantly affecting vision"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672775", 
            "org_study_id": "AGS-16C3F-12-2"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1 AGS-16C3F highest dose", 
                "Cohort 0 AGS-16C3F higher dose", 
                "Cohort (-1) AGS-16C3F high dose", 
                "Cohort (-2) AGS-16C3F middle dose", 
                "Cohort (-3) AGS-16C3F low dose", 
                "Cohort (-4) AGS-16C3F lowest dose", 
                "AGS-16C3F in RCC Subjects with  Clear Cell Histology", 
                "AGS-16C3F in RCC Subjects with  Papillary Histology"
            ], 
            "description": "intravenous (IV) infusion", 
            "intervention_name": "AGS-16C3F", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Renal Cell Carcinoma", 
            "Pharmacokinetics of AGS-16C3F", 
            "AGS-16C3F"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detriot", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Cross Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "British Columbia Cancer Agency"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "London Health Sciences Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3T 1E2"
                    }, 
                    "name": "Jewish General Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology", 
        "overall_contact": {
            "email": "Clinical@Agensys.com", 
            "last_name": "Agensys Clinical Research and Development", 
            "phone": "424-280-5000"
        }, 
        "overall_official": {
            "affiliation": "Agensys, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Concentration at end of infusion (Ceoi) or maximum observed concentrations (Cmax), Trough concentration (Ctrough), time to maximum concentration (Tmax), partial area under the serum concentration-time curve (AUC\u03c4), terminal or apparent half-life (t1/2), systemic clearance (CL), and volume of distribution at steady state (Vss)", 
                "measure": "Pharmacokinetic profile for total antibody (TAb), antibody drug conjugate (ADC), and monomethyl auristatin F (MMAF): Ceoi or Cmax, Ctrough, Tmax,  AUC\u03c4, t1/2, CL, and Vss", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, 4, 8, 15, 22, 43, 64, 65, 66, 67, 71, 78, and 92"
            }, 
            {
                "measure": "Incidence of antidrug antibody formation to human native antibody (AGS-16C) and antibody drug conjugate (AGS-16C3F)", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Determined from the subjects' best response and will include complete response (CR) and partial response (PR)", 
                "measure": "Tumor response: objective response rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Determined from the subjects' best response will include complete response (CR) partial response (PR), and stable disease (SD)", 
                "measure": "Tumor response:  disease control rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Tumor response: Changes in bone scans", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 13 and every 12 weeks thereafter"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Agensys, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}